SS
CTNM

SBI Securities’s Contineum Therapeutics CTNM Stock Holding History

SBI Securities’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$12 – 4262
2025
Q3 		$12 Sell
1
-283
-100% -$2.28K ﹤0.01% 4017
2025
Q2 		$1.13K Buy
284
+264
+1,320% +$1.15K ﹤0.01% 2629
2025
Q1 		$140 Buy
+20
New +$182 ﹤0.01% 3336

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SBI Securities's CTNM Position: Q4 2025 in Review

SBI Securities sold out of Contineum Therapeutics (CTNM) in Q4 2025, closing a stake of 1 share — an estimated $12 sold.

SBI Securities first reported a position in CTNM in Q1 2025 and held it in 3 quarters. The position peaked at $1.13K in Q2 2025. 80 funds tracked by Wall St. Rank hold CTNM as of Q4 2025.

  • SBI Securities reported no remaining Contineum Therapeutics position as of Q4 2025 after selling out during the quarter.
  • SBI Securities sold 1 Contineum Therapeutics share in Q4 2025, an estimated $12.
  • SBI Securities first reported a position in Contineum Therapeutics in Q1 2025 and held it in 3 quarters.
  • SBI Securities's Contineum Therapeutics position peaked at $1.13K in Q2 2025.
  • 80 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q4 2025.

Based on SBI Securities's 13F filing for Q4 2025, filed 3 Feb 2026.